Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study

JCI insight

Volumn 3, Issue 8, 2018, Pages

  Blau, Jenny E ^a,b   Bauman, Viviana ^a   Conway, Ellen M ^a   Piaggi, Paolo ^c   Walter, Mary F ^a   Wright, Elizabeth C ^a   Bernstein, Shanna ^d   Courville, Amber B ^d   Collins, Michael T ^e   Rother, Kristina I ^a   Taylor, Simeon I ^a,f  

^a National Institute of Diabetes and Digestive and Kidney Diseases

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d Hatfield   (United Kingdom)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bone Biology; Bone disease; Diabetes; Endocrinology

Indexed keywords

1,25-DIHYDROXYVITAMIN D; CANAGLIFLOZIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; VITAMIN D;

ADULT; ADVERSE EVENT; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; FRACTURE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PATHOPHYSIOLOGY; PHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; CANAGLIFLOZIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; FRACTURES, BONE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PLACEBOS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VITAMIN D;

EID: 85050289906     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.99123     Document Type: Article

References (0)